Docebo (DCBO) launches US$70m issuer bid as preliminary Q2 revenue exceeds prior guidance

Docebo Inc. (NASDAQ: DCBO; TSX: DCBO) has approved a substantial issuer bid to repurchase and cancel up to US$70 million of its common shares at US$20.40 apiece. The proposed offer could remove approximately 13.8% of the company’s outstanding shares on a non-diluted basis. Docebo disclosed the capital-return plan alongside preliminary second-quarter results showing total revenue above its previous guidance range and adjusted EBITDA in line with expectations. The enterprise learning software provider also raised its full-year subscription and total revenue forecasts while leaving its adjusted EBITDA range unchanged. Docebo shares closed at US$20.38 on Nasdaq on July 17, rising approximately 9.9% and finishing almost exactly at the proposed tender price.

What exactly is Docebo offering shareholders through its US$70 million issuer bid?

At US$20.40 per share, the offer would allow Docebo to cancel approximately 3.43 million common shares if fully subscribed. The tender is not conditional on a minimum number of shares being deposited, although other customary conditions will apply.

If shareholders tender stock worth more than the US$70 million limit, Docebo will purchase the deposited shares on a pro rata basis. Investors owning fewer than 100 shares who tender their entire positions will qualify for odd-lot priority and will not be subject to proration.

The US$20.40 price represented an approximately 10% premium to Docebo’s July 16 Nasdaq closing price of US$18.54. The market largely eliminated that premium following the announcement, with the stock finishing July 17 at US$20.38. That leaves investors with little direct price advantage from tendering at current levels, although the spread could reopen if the shares decline before the offer expires.

The formal offer documents are expected to be distributed around July 21. Until those documents are filed, the offer has not formally commenced. Docebo has also temporarily suspended purchases under the normal course issuer bid that began on May 20.

Canadian shareholders face an additional consideration. For Canadian income tax purposes, part of the tender proceeds may generally be treated as a deemed dividend because the US$20.40 purchase price exceeds Docebo’s estimated paid-up capital of C$10.97 per share. The precise consequences will depend on each shareholder’s circumstances.

Why is Docebo borrowing US$60 million to repurchase shares at US$20.40 apiece?

Docebo intends to finance approximately US$10 million of the offer using cash and the remaining US$60 million through its credit facility. The company recently increased that facility from US$100 million to US$150 million.

This means roughly 86% of the tender consideration will be debt-funded. Management’s rationale is that Docebo’s recent market valuation does not fully reflect the company’s business quality or future prospects, making the repurchase an attractive use of capital.

The strategy has a clear potential benefit. If the entire 13.8% share block is cancelled, future earnings and cash flow would be distributed across a meaningfully smaller share base. Even without a corresponding increase in absolute profit, the reduction could support higher earnings per share and free cash flow per share.

The trade-off is greater financial leverage. Docebo expects to report US$45.7 million in cash and US$88 million in total borrowings at June 30. Before considering subsequent cash generation or transaction costs, using US$10 million of cash and adding US$60 million of debt would leave the company with approximately US$35.7 million in cash and US$148 million in gross borrowings.

That would translate into rough pro forma net debt of US$112.3 million. Compared with the midpoint of Docebo’s US$54.5 million to US$56.5 million full-year adjusted EBITDA forecast, pro forma net debt would equal approximately two times expected adjusted EBITDA. Gross borrowings would approach 2.7 times the same midpoint.

Those calculations are simplified and do not incorporate cash produced between June 30 and the offer’s completion. They nevertheless show that the transaction represents a material balance-sheet decision, not simply the deployment of surplus cash.

How does the latest tender extend Docebo’s capital-return program during 2026?

This is Docebo’s second substantial issuer bid of 2026 at the same US$20.40 purchase price. The company completed a US$60 million tender in March, cancelling approximately 2.94 million shares, or 10.2% of the shares outstanding when that earlier offer was announced.

The first tender was oversubscribed. Docebo received deposits covering approximately 3.81 million shares, resulting in most non-odd-lot investors having about 74.5% of their successfully tendered shares purchased.

If the new US$70 million offer is completed in full, Docebo will have spent US$130 million across the two substantial issuer bids and cancelled approximately 6.37 million shares. That would equal a little more than 22% of the share count that existed before the first tender, although subsequent equity issuance and purchases under other programs can affect the precise comparison.

The repeated use of US$20.40 also sends a valuation signal. The board was prepared to commit US$60 million at that price earlier in the year and is now proposing to deploy another US$70 million at the same valuation.

However, the financing mix has become an important part of the investment case. Repurchasing undervalued stock can create substantial per-share value, but the benefit depends on Docebo generating enough durable cash flow to service the additional debt without limiting product investment, acquisitions or commercial expansion.

What do Docebo’s preliminary second-quarter results reveal about operating momentum?

Docebo expects second-quarter subscription revenue of US$63.5 million to US$63.7 million, representing growth of 11.2% to 11.6% from the prior year. Total revenue is expected to range from US$68.3 million to US$68.5 million, an increase of 12.5% to 12.9%.

The total revenue midpoint of US$68.4 million is US$1.6 million above the midpoint of Docebo’s previous US$66.7 million to US$66.9 million guidance. That represents an approximate 2.4% improvement relative to the earlier forecast.

Adjusted EBITDA is expected to range from US$10.9 million to US$11.1 million. The midpoint of US$11 million matches the midpoint of the company’s prior guidance, even though revenue came in higher.

At the midpoint, adjusted EBITDA increased about 19.6% from the US$9.2 million reported in the prior-year quarter. The corresponding adjusted EBITDA margin would be approximately 16.1%, compared with about 15.2% a year earlier.

The year-over-year margin improvement suggests Docebo is producing operating leverage. However, the fact that incremental revenue above guidance did not lead to an increase in the quarterly EBITDA estimate may indicate differences in revenue mix, investment timing or associated delivery expenses. The final results and management commentary on August 7 should provide more detail.

Investors should also remember that the figures remain preliminary and unaudited. They are subject to management and audit committee review, completion of normal closing procedures and review by KPMG LLP.

How should investors interpret Docebo’s 9.5% ARR growth after the OEM decline?

Annual recurring revenue is expected to reach US$255.1 million, up 9.5% from US$233.1 million a year earlier. Foreign exchange reduced the quarter-end figure by approximately US$400,000.

The headline growth rate is lower than the 10.6% ARR growth reported at the end of the first quarter. However, the comparison continues to be affected by the contraction of Docebo’s largest original equipment manufacturer relationship.

That customer is expected to account for only 2.5% of ARR, down from 8.4% one year earlier. Based on the reported totals, its implied ARR contribution declined from approximately US$19.6 million to around US$6.4 million. The roughly US$13.2 million reduction creates a substantial drag on consolidated ARR growth.

Excluding the largest OEM customer, acquired ARR and the foreign-exchange impact, Docebo estimates that ARR increased approximately 13.9%. That underlying growth rate presents a healthier picture of the continuing business, although it is an adjusted metric and investors should evaluate it alongside reported ARR.

The falling OEM concentration also reduces dependency on a single distribution relationship. The short-term effect is slower headline growth, but the longer-term business could become more diversified if direct enterprise sales and other partnerships replace the lost contribution.

The key question is whether underlying ARR growth can remain in the low-to-mid teens after the OEM comparison becomes less significant. Customer retention, net dollar retention, new enterprise wins and the contribution from recent acquisitions will all be important indicators.

What does Docebo’s revised full-year guidance imply for revenue and software margins?

Docebo raised its fiscal 2026 subscription revenue forecast to US$255.5 million to US$257.5 million from US$253.5 million to US$255.5 million. The midpoint increased by US$2 million to US$256.5 million.

Total revenue guidance increased more substantially, moving to US$274.5 million to US$276.5 million from US$271 million to US$273 million. The midpoint rose by US$3.5 million to US$275.5 million.

Adjusted EBITDA guidance remains unchanged at US$54.5 million to US$56.5 million. At the respective midpoints, the updated outlook implies an adjusted EBITDA margin of approximately 20.1%, slightly below the 20.4% implied by the previous revenue forecast.

This does not necessarily signal worsening cost control. The higher revenue outlook may include professional services or other revenue carrying different margins, while the company may also be choosing to reinvest part of the revenue outperformance. Still, investors will want to understand why the improved top-line outlook has not raised the annual profit range.

Third-quarter guidance points to a more pronounced margin expansion. Docebo expects subscription revenue of US$64.9 million to US$65.1 million, total revenue of US$69.5 million to US$69.7 million and adjusted EBITDA of US$15.9 million to US$16.1 million.

At the midpoints, the third-quarter adjusted EBITDA margin would reach approximately 23%, compared with about 16.1% in the preliminary second quarter. Delivering that sequential increase will be important to achieving the full-year profitability target.

How will Intercap’s participation affect control and minority shareholder proration?

Intercap Inc. beneficially owns approximately 63.9% of Docebo’s outstanding common shares and intends to participate in a manner that preserves at least its existing percentage ownership.

That commitment means the controlling shareholder is not using the tender to reduce its influence. If the transaction is completed as planned, Intercap should continue controlling nearly two-thirds of the company while the overall share count falls.

Intercap’s participation also leaves a smaller portion of the offer available economically to minority investors. If tenders exceed the maximum, non-odd-lot shareholders should expect proration, as occurred during the March transaction.

The earlier issuer bid increased Intercap’s ownership from approximately 56.6% to 61.6% because the company cancelled a larger proportion of shares held by other investors. Its position has since increased to 63.9%. The latest commitment to maintain at least that percentage indicates that concentrated ownership will remain a defining governance characteristic.

Concentrated control can support long-term decision-making and reduce pressure to optimize short-term results. It also limits the influence of minority shareholders over board composition, capital allocation and strategic alternatives.

What are the key takeaways from Docebo’s issuer bid and revised 2026 outlook?

• Docebo plans to spend up to US$70 million repurchasing shares at US$20.40 apiece, potentially cancelling approximately 3.43 million shares or 13.8% of the non-diluted share count.
• Approximately US$60 million of the offer will be financed through additional borrowing, making the transaction primarily a leveraged capital-return program rather than a cash-funded repurchase.
• Preliminary second-quarter total revenue of US$68.3 million to US$68.5 million is about US$1.6 million above the midpoint of Docebo’s previous guidance, while adjusted EBITDA remains within the previously forecast range.
• Reported ARR increased 9.5% to US$255.1 million, but growth was approximately 13.9% after excluding the largest OEM customer, acquired ARR and foreign-exchange effects.
• Docebo raised the midpoint of its full-year total revenue forecast by US$3.5 million and its subscription revenue midpoint by US$2 million, while keeping adjusted EBITDA guidance unchanged.
• The company expects third-quarter adjusted EBITDA of approximately US$16 million, implying a margin near 23% and making Q3 execution central to the full-year profitability outlook.
• This is Docebo’s second substantial issuer bid of 2026. Full completion would bring combined spending across the two tenders to US$130 million and shares cancelled to approximately 6.37 million.
• Intercap intends to preserve at least its 63.9% ownership, meaning the transaction will reduce the public share count without materially weakening the controlling shareholder’s position.